Corporate Events

Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the first half ending September 30, 2025 and full year of Fiscal Year Ending March 31, 2026. For the first half, the company expected net sales of JPY 44,300 million compared to previous guidance of JPY 44,300 million, Operating loss of JPY 7,700 million compared to previous guidance Operating profit of JPY 2,300 million, Profit attributable to owners of parent of JPY 6,200 million compared to previous guidance of JPY 6,200 million and Basic earnings per share of JPY 149.74. For the Full year, the company expected net sales of JPY 91,500 million compared to previous guidance of JPY 91,500 million, Operating loss of JPY 4,000 million compared to previous guidance Operating profit of JPY 6,000 million, Profit attributable to owners of parent of JPY 12,300 million compared to previous guidance of JPY 12,300 million and Basic earnings per share of JPY 297.07. In the interim period for the six months ending September 30, 2025, the Company plans to enter into a new technology licensing agreement that was not incorporated in the initial forecast. Due to recording the upfront payment from this agreement as R&D expenses, selling, general and administrative expenses are expected to increase by JPY 10,000 million from the initial forecast to JPY 29,600 million, resulting in operating profit and ordinary profit each decreasing by JPY 10,000 million. The Company expects to record an operating loss of JPY 7,700 million. However, regarding profit attributable to owners of parent for the six months ending September 30, 2025, by increasing gain on sale of investment securities by JPY 10,000 million from the initial forecast as extraordinary income, the Company maintains the initial forecast of JPY 6,200 million with no revisions. With respect to full year profit forecasts for the fiscal year ending March 31, 2026, based on the revised performance for the six months ending September 30, 2025, operating profit has been revised to a loss of JPY 4,000 million, a decrease of JPY 10,000 million from the initial forecast (-% year on year), while profit attributable to owners of parent remains unchanged at JPY 12,300 million, the same as the initial forecast (an increase of 2.8% year on year).

Kissei Pharmaceutical Co., Ltd., Board Meeting, Jun 24, 2025. Agenda: To consider disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers.

Kissei Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Jul 29, 2025

Kissei Pharmaceutical Co., Ltd. expected to report Q1 2026 results on July 31, 2025. This event was calculated by S&P Global (Created on May 22, 2025).

Kissei Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first half and full year of Fiscal Year Ending March 31, 2026. For the first half, the company expected net sales of JPY 44,300 million, Operating profit of JPY 2,300 million, Profit attributable to owners of parent of JPY 6,200 million and Basic earnings per share of JPY 149.74. For the Full year, the company expected net sales of JPY 91,500 million, Operating profit of JPY 6,000 million, Profit attributable to owners of parent of JPY 12,300 million and Basic earnings per share of JPY 297.07.

The company closed its plan on May 8, 2025.

From May 7, 2025 to May 8, 2025, the company has repurchased 1,369,200 shares, representing 3.2% for ¥5,216.65 million. With this, the company has completed the repurchase of 1,369,200 shares, representing 3.2% for ¥5,216.65 million under the buyback announced on May 7, 2025.

The Board of Directors of Kissei Pharmaceutical Co., Ltd. has authorized a buyback plan on May 7, 2025.

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,400,000 shares, representing 3.27% of its share capital, for ¥ 5,334 million. The shares will be repurchased at price of ¥ 3,810 per share. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. As of April 30, 2025, the company had 42,805,038 shares outstanding (excluding treasury shares) and 5,106,147 shares in treasury.

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2025.

Kissei Pharmaceutical Co., Ltd., Board Meeting, May 07, 2025. Agenda: To discuss Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading System and the Cancellation of Treasury Shares.

Kissei Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 07, 2025

Ferring Pharma Co., Ltd. and Kissei Pharmaceutical Co., Ltd. announced that they will terminate their co-promotion agreement for Minirin Melt and Desmopressin formulations. The active ingredient of the aforesaid drugs is desmopressin acetate hydrate, which was developed by Ferring. Ferring and Kissei have had a co-promotion in Japan since September 2019, and with the termination of this co-promotion agreement, Kissei will suspend promotion activities for the drug on March 31, 2025. Furthermore, Ferring will be solely responsible for promotion activities for these drugs from April 1, 2025. MINIRIN MELT ® OD Tablets 25g and 50g- Nocturia due to nocturnal polyuria in males; MINIRIN MELT ® OD Tablets 60g, 120g, and 240g- Nocturnal enuresis resulted from decrease of urine osmolality or urine specific gravity*, central diabetes insipidus 120g and 240g only; DESMOPRESSIN Spray 2.5 Ferring- Central diabetes insipidus; DESMOPRESSIN injection 4 Ferring- Hemostatic management of spontaneous or traumatic hemorrhage and bleeding during tooth extraction or operation in the patients with following diseases: Mild/moderate hemophilia A (with 2% or higher factor VIII coagulative activity) Type I/Type IIA von Willebrand disease.

Kissei Pharmaceutical Co., Ltd. Presents at BIO Partnering @JPM Week, Jan-13-2025 . Venue: San Francisco Marriott Marquis, San Francisco, California, United States.

Kissei Pharmaceutical Co., Ltd. announced that it has entered into a sub-license agreement with Tai Tien Pharmaceuticals Co., Ltd. to license development and commercialization rights in Taiwan for Tavalisse®? (fostamatinib disodium hexahydrate), a spleen tyrosine kinase (SYK) inhibitor discovered by Rigel Pharmaceuticals Inc. By executing this agreement, Tai Tien will gain the rights to develop and commercialize fostamatinib in Taiwan. Kissei will receive an upfront payment and milestone payments based on the progress of commercialization in Taiwan from Tai Tien and will supply the formulation to Tai Tien. Kissei will continue to advance the development of Tavalisse in its licensed regions through collaboration with partner companies, striving to further contribute to the treatment of chronic ITP, an intractable disease.

Certain Common Stock of CG Oncology, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2025. These Common Stock will be under lockup for 91 days starting from 12-DEC-2024 to 13-MAR-2025. Details: The directors and officers and certain of their affiliates holding shares of our common stock have entered into lock-up agreements with the underwriters agreeing that, subject to certain exceptions, without the prior written consent of Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of this prospectus (the restricted period): offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock; enter into any hedging, swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock; or submit or file any registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock

Certain Options of CG Oncology, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2025. These Options will be under lockup for 91 days starting from 12-DEC-2024 to 13-MAR-2025. Details: The directors and officers and certain of their affiliates holding shares of our common stock have entered into lock-up agreements with the underwriters agreeing that, subject to certain exceptions, without the prior written consent of Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on behalf of the underwriters, we and they will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of this prospectus (the restricted period): offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock; enter into any hedging, swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our common stock; or submit or file any registration statement with the SEC relating to the offering of any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock

CG Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $224 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,000,000 Price\Range: $28

CG Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $310.04 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 8,000,000 Price\Range: $38.755

Kissei Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 03, 2025

Kissei Pharmaceutical Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2025. For the full year, the company now expects net sales of JPY 86,500 million, Operating profit of JPY 5,000 million, Profit attributable to owners of parent of JPY 11,700 million and Basic earnings per share of JPY 268.21 against previous guidance of net sales of JPY 83,000 million, Operating profit of JPY 4,200 million, Profit attributable to owners of parent of JPY 11,300 million. As a result of a review taking the financial results for the six months ended September 30, 2024 and the current business environment into consideration, the Company has revised the net sales forecast upward by JPY 3,500 million for the Pharmaceutical Business.

Kissei Pharmaceutical Co., Ltd. announced dividend of JPY 45.00 per share for the second quarter ended September 30, 2024 against JPY 41.00 per share a year ago. Scheduled date of commencing dividend payments is December 3, 2024.

Kissei Pharmaceutical Co., Ltd., ¥ 45.0, Cash Dividend, Mar-28-2025

From November 5, 2024 to November 6, 2024, the company has repurchased 1,400,000 shares, representing 3.17% for ¥5,292 million. With this, the company has completed the repurchase of 1,400,000 shares, representing 3.17% for ¥5,292 million under the buyback announced on November 5, 2024.

The company closed its plan on November 6, 2024.

Kissei Pharmaceutical Co., Ltd., Board Meeting, Nov 05, 2024. Agenda: Reasons for acquisition and cancellation of treasury shares, to execute a flexible capital policy in response to changes in the business environment , while improving capital efficiency and enhancing shareholder returns; and to consider other matters.

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces a share repurchase program. Under the program, the company will repurchase up to 1,400,000 shares, representing 3.17% of its share capital, for ¥ 5,292 million. The shares will be repurchased at price of ¥ 3,780 per share. The company will repurchase its shares in order to implement a flexible capital policy which responds to changes in the business environment, improve capital efficiency, and enhance shareholder returns. The shares repurchased will be cancelled. As of October 31, 2024, the company had 44,205,187 shares outstanding (excluding treasury shares) and 5,105,998 shares in treasury.

The Board of Directors of Kissei Pharmaceutical Co., Ltd. has authorized a buyback plan on November 5, 2024.

Kissei Pharmaceutical Co., Ltd., H1 2025 Earnings Call, Nov 07, 2024

Kissei Pharmaceutical Co., Ltd. announced that Theramex (UK), to which Kissei licensed out its technology for Linzagolix, a uterine fibroid treatment discovered and developed by Kissei, has made its first commercial sale of the drug in Germany. YSELTY® is a GnRH receptor antagonist that antagonizes GnRH at GnRH receptors in the pituitary gland and suppresses the secretion of gonadotropin, a gonadotropic hormone, thereby decreasing estrogen production in the ovary and improving bleeding and pain symptoms in patients with uterine fibroids. Phase III clinical trials conducted in the U.S. and Europe confirmed the efficacy of the product not only in combination with Add-back therapy but also in the non-combination group, and in June 2022, the European Commission (EC), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and other regulatory agencies granted marketing approval for the indication of moderate to severe uterine fibroids in adult women of reproductive age. YSELTY® is a GnRH antagonist that can be used for uterine fibroid patients who cannot take hormonal agents, providing a new treatment option tailored to individual patient conditions and needs. The company expects that YSELTY® will be available in many countries in the territory licensed to Theramex through Theramex. The agent is being developed for the treatment of uterine fibroids and endometriosis in Japan, and it is being developed by out-licensed companies such as Theramex Inc, overseas. The company are committed to making efforts to ensure that this drug will contribute widely to improve the QOL of patients around the world.

Kissei Pharmaceutical Co., Ltd. and Reborna Biosciences Inc. signed a research collaboration agreement on drug discovery in the field of genetic rare diseases. Under this agreement, both companies will collaborate on drug discovery research targeting intractable genetic rare diseases using Reborna's proprietary RNA-targeting small molecule drug discovery technology. Kissei will pay Reborna an upfront payment, research expenses, as well as milestone payments based on the progress of research, development, and sales, and royalties based on sales. In addition, Kissei will retain the right to develop and commercialize worldwide the development candidate compounds discovered through the collaboration and that meet the target criteria.

Kissei Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 05, 2024

Kissei Pharmaceutical Co., Ltd. (TSE:4547) agreed to acquire exclusive development and commercialization rights acute myeloid leukemia drug from Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL) on September 3, 2024. A cash consideration of $10 million will be paid by Kissei Pharmaceutical Co., Ltd. Kissei Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of $152.5 million cash. As part of consideration, $162.5 million is paid towards assets of exclusive development and commercialization rights acute myeloid leukemia drug. Pursuant to the License Agreement, Kissei is responsible for companion diagnostic development in Japan, for which Rigel will share fifty percent of the costs incurred by Kissei, up to $3.0 million, which are creditable against future milestones and transfer price payments owed to Rigel.

Rigel Pharmaceuticals, Inc. announced it has entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize REZLIDHIA® (olutasidenib) in all current and potential indications in Japan, the Republic of Korea (Korea) and Taiwan. REZLIDHIA is commercially available to patients in the U.S. for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). Rigel has an existing agreement with Kissei to develop and commercialize TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of chronic immune thrombocytopenia (ITP) and in all other potential indications in Japan, China, Taiwan and the Republic of Korea. Under the terms of the agreement, Rigel will receive an upfront cash payment of $10.0 million from Kissei, with the potential for up to an additional $152.5 million in development, regulatory and commercial milestone payments. Rigel will receive product transfer price payments in the mid-twenty to lower-thirty percent range based on tiered net sales for the exclusive supply of REZLIDHIA. Kissei receives exclusive rights to REZLIDHIA in AML and all future indications in Japan, Korea and Taiwan. Kissei will initially seek approval for REZLIDHIA in Japan for R/R mIDH1 AML and will be responsible for conducting clinical studies as required by the Japanese regulatory agency, Pharmaceuticals and Medical Devices Agency (PMDA). Rigel retains the global rights, excluding these Asian countries, to develop and commercialize REZLIDHIA for all indications, and is currently exploring other ex-US partnership opportunities.